Walmart Closing Most In-Store McDonald’s By Summer’s End

The pandemic is forcing retailers to rethink their strategy to their brick-and-mortar locations. One of those retailers, Walmart, has already closed several in-store McDonald’s locations they consider their physical partnerships.

On this episode of Marketscale TV, Voice of B2B, Daniel Litwin talked with Prof. Ed Fox, Professor of Marketing, Director, JCPenney Center for Retail Excellence at Southern Methodist University’s Cox School of Business. Also joining in on the conversation was Dr. P.K. Kannan, Dean’s Chair, Marketing Science, University of Maryland Robert H. Smith School of Business.

The trio explored the partnership between this retail and fast-food giant, as Walmart plans to close hundreds of in-store McDonald’s after sluggish demands due to the pandemic. Only 150 stores will remain at the end of summer 2021.

“The McDonald’s/Walmart case is amplified,” Fox said. “It’s the largest of these kinds of partnerships. I think it’s useful to look at this as one of two things has to be happening: either there’s a symbiosis. In this case, one of the retailers, McDonald’s, is borrowing traffic from Walmart and taking advantage of that traffic, and having access to many more customers. Or, there should be synergy, where both benefit from that relationship.”

Low foot traffic is undoubtedly driving the downturn for these McDonald’s, as consumers shift to a digital-first approach. So, it seems Walmart is examining this symbiotic relationship. Most of McDonald’s sales came from drive-thrus during the pandemic, so without in-store drive-thrus, business on both sides was lost.

“If you look at it from the viewpoint of McDonald’s,” Kannan said. “During the COVID pandemic, 70 percent of their sales came from drive-throughs, and even as they are looking forward when Walmart is changing their store formats … McDonald’s is facing a challenge because they must also upgrade with these new stores.”

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More
organoids
Growing the Future of Cancer Research: Inside the Promise of Organoids
April 19, 2025

In an era where precision and predictability define the future of oncology, organoid technology is emerging as a transformative tool in drug discovery. These miniature, lab-grown 3D tissues mirror real human biology more closely than traditional 2D models or even animal systems, offering researchers the potential to predict patient-specific drug responses. As organoids become more…

Read More